159eur
5,0 %
Date:2024-04-26Time:17:29:58Latest report:Q4-2023List:First NorthTicker:FARON
Market Cap:114 meurEnterprise Value:121 meurNet Sales:- meurEarnings:-30,9 meurEmployees:0ISIN:FI4000153309

Ratios

10-year key figure history for Faron Pharmaceuticals turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Faron Pharmaceuticals with index and moving average MA50 and MA200.

Stockprice:1,59
MA50:1,70
MA200:3,03
Price/MA200:-47,6 %
RSI (14):50,7
Price/MA50:-6,6 %

Description

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.

Pharmaceuticals